ArticleCancer cell international2025
Ferroptosis resistance-related TEP1 as a novel prognostic biomarker involved in immune cell infiltration and tumour progression in glioblastoma.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ferroptosis and metabolic reprogramming in the immunosuppressive microenvironment of glioblastoma: emerging mechanisms and novel strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundTEP1 is a ribonucleoprotein complex component that binds to telomerase, and its role in GBM development is unclear. This study was designed to investigate the regulatory mechanism of TEP1 in GBM development.
methodsTEP1 expression was verified using the TCGA and CGGA databases. Kaplan–Meier survival curve, univariate Cox regression, and multivariate Cox regression analyses were employed to assess the prognostic and predictive value of TEP1. KEGG and GO analyses were conducted to identify signalling pathways and functional gene sets enriched in TEP1-related genes. Immune infiltration was evaluated using the CIBERSORT and ssGSEA algorithms. Single-cell sequencing data were utilized to pinpoint TEP1-enriched cell populations. Drug susceptibility data from the CCLE, GDSC, and CTRP databases were integrated to explore potential therapeutic implications. Further validation was performed using immunofluorescence, quantitative real-time PCR, Western blotting, and in vitro and in vivo ferroptosis assays.
resultsTEP1 expression was significantly elevated in GBM tissues compared to normal brain tissues, correlating with copy number alterations and poor overall survival. Elevated TEP1 expression correlated with increased tumour malignancy, IDH wild-type status, and radiotherapy resistance. Functional analyses revealed significant associations between TEP1 expression and pathways involved in lipid metabolism, apoptosis, immune response, cell cycle regulation, and ferroptosis. Immune profiling highlighted enrichment of TEP1 in immune cells, particularly plasmacytoid dendritic cells and natural killer T cells. Elevated TEP1 expression was associated with altered sensitivity to various anticancer drugs, notably ferroptosis modulators. In vitro and in vivo experiments confirmed that TEP1 significantly inhibited ferroptosis induced by RSL3, thereby promoting GBM cell survival and tumour progression.
conclusionOverall, we found that TEP1 is a promising biomarker for GBM and reduces the susceptibility of GBM cells to ferroptosis, providing a novel target for GBM treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.